Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Structure Therapeutics Inc. American Depositary Shares

Healthcare US GPCR

39.04USD
1.54(4.11%)

Last update at 2026-06-04T17:44:00Z

Day Range

37.9039.71
LowHigh

52 Week Range

15.8094.90
LowHigh

Fundamentals

  • Previous Close 37.50
  • Market Cap3317.52M
  • Volume342479
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-185.13101M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.4

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -140.68700M -122.21600M -89.38400M -51.30400M -0.03782M
Minority interest - - - 0.00000M -
Net income -141.20200M -122.52600M -89.62000M -51.32100M -0.03805M
Selling general administrative 61.55M 49.41M 32.67M 16.37M 0.00859M
Selling and marketing expenses - - 0.00000M - -
Gross profit -3.89928M -2.59830M -0.94917M - -
Reconciled depreciation 1.33M 0.99M 0.29M 0.28M 0.00007M
Ebit -140.68700M -158.22800M -102.77500M -52.83800M -0.03770M
Ebitda -136.78771M -157.23600M -102.48000M -52.56100M -0.03762M
Depreciation and amortization 3.90M 0.99M 0.29M 0.28M 0.00007M
Non operating income net other - - - - -
Operating income -287.56753M -158.22800M -102.77500M -52.56100M -0.03770M
Other operating expenses 287.57M 158.23M 102.78M 52.56M 0.04M
Interest expense - - 13.39M -1.53400M 0.00584M
Tax provision 0.52M 0.31M 0.24M 0.02M 0.00023M
Interest income - - - - -
Net interest income 35.87M 36.01M 13.39M 1.26M -0.00012M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.52M 0.31M 0.24M 0.02M 0.00023M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 283.67M 158.23M 102.78M 52.56M 0.04M
Cost of revenue 3.90M 2.60M 0.95M - -
Total other income expense net 146.51M 36.01M 13.39M 1.26M -0.00012M
Discontinued operations - - - - -
Net income from continuing ops -141.20200M -122.52600M -89.62000M -51.32100M -0.03805M
Net income applicable to common shares - - - - -43.76500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1583.92M 903.33M 482.02M 97.84M 0.11M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 124.11M 7.69M 6.29M 2.25M 1.94M
Total liab 67.54M 38.49M 29.05M 212.99M 0.18M
Total stockholder equity 1516.38M 864.84M 452.97M -115.14000M -0.06474M
Deferred long term liab - - - 3.40M 0.10M
Other current liab 46.54M 26.30M 18.20M 6.74M -3.47569M
Common stock 0.02M 0.02M 0.01M 0.00100M 0.00000M
Capital stock 0.02M 0.02M 0.01M 0.00100M 0.00000M
Retained earnings -470.30000M -329.09800M -206.57204M -116.95200M -0.06474M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 3.46M 0.11M
Cash 799.62M 169.51M 129.79M 90.84M 0.11M
Cash and equivalents - - - - -
Total current liabilities 63.28M 36.02M 24.74M 13.01M 0.00866M
Current deferred revenue - - 0.36M - -
Net debt -793.13600M -165.64800M -124.33902M -90.58100M -0.10468M
Short term debt 2.88M 1.70M 1.44M 0.26M 0.00035M
Short long term debt - - - - -
Short long term debt total 6.49M 3.86M 5.45M 0.26M 0.00062M
Other stockholder equity 1985.60M 1193.01M 659.00M -131.09400M -
Property plant equipment - - - 1.29M 1.79M
Total current assets 1570.30M 891.21M 473.61M 93.09M 0.11M
Long term investments - - - - -
Net tangible assets - - - -115.14000M -64.73500M
Short term investments 646.57M 714.01M 337.53M 64.75M 0.00200M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 13.86M 8.02M 4.74M 6.01M 3.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.05M 0.91M 0.52M -0.11000M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.72M 5.11M 0.04M 3.46M 0.00011M
Deferred long term asset charges - - - - -
Non current assets total 13.62M 12.12M 8.41M 4.76M 0.00191M
Capital lease obligations 6.49M 3.86M 5.45M 0.26M 0.00062M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 93.41M -358.90900M -268.34200M -62.10800M 0.02M
Change to liabilities - - - 2.15M 1.90M
Total cashflows from investing activities 89.80M -358.90900M -268.34200M -62.10800M 17.86M
Net borrowings - - - - -
Total cash from financing activities 762.52M 515.26M 451.53M 29.01M 0.10M
Change to operating activities - - - 0.81M 2.17M
Net income -141.20200M -122.52600M -89.62000M -51.32100M -0.03805M
Change in cash 630.12M 39.72M 103.70M -79.21400M 0.09M
Begin period cash flow 169.51M 129.79M 26.09M 105.31M 0.02M
End period cash flow 799.63M 169.51M 129.79M 26.09M 0.11M
Total cash from operating activities -222.19900M -116.63600M -79.48800M -46.12000M -0.03216M
Issuance of capital stock 665.71M 514.57M 472.30M 31.50M 0.10M
Depreciation 1.33M 0.99M 0.29M 0.28M 0.00007M
Other cashflows from investing activities 10.25M -357.61900M -0.23138M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities -4.66163M 0.69M -20.76500M 29.01M 0.10M
Change to netincome - - - 1.96M 1.71M
Capital expenditures 3.61M 1.29M 2.17M 0.15M 0.00121M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -88.27384M 2.96M 6.97M 2.97M 0.00406M
Stock based compensation 28.99M 18.79M 8.19M 2.51M 0.00149M
Other non cash items -23.04716M -16.86000M -5.32000M -0.55800M 0.00024M
Free cash flow -225.81300M -117.92600M -81.65500M -46.27500M -0.03337M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
GPCR
Structure Therapeutics Inc. American Depositary Shares		 1.54 4.11% 39.04 - - - 2.25 -13.463
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Structure Therapeutics Inc. American Depositary Shares

601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Raymond C. Stevens Ph.D. CEO & Director 1964
Dr. Yingli Ma Ph.D. Chief Technology Officer 1974
Dr. Mark A. Bach M.D., Ph.D. Chief Medical Officer 1957
Mr. Jun S. Yoon Co- Founder, CFO & Secretary 1978
Dr. Xichen Lin Ph.D. Chief Scientific Officer 1974
Mr. Tony Peng Senior Vice President of Legal NA
Mr. Bob Gatmaitan Senior Vice President of People NA
Dr. Hui Lei Ph.D. Senior Vice President of Chemistry NA
Dr. Fang Zhang Ph.D. Executive VP & Head of Biology NA
Ms. Lani Ibarra Senior Vice President of Clinical Development Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions